M-A | Em pacientes com síndrome coronariana aguda, uma abordagem orientada (p. ex., função plaquetária ou teste genético) para a terapia com inibidores de P2Y12 pode reduzir os eventos adversos cardiovasculares maiores sem aumentar o risco de sangramento.

Comparative effects of guided vs. potent P2Y₁₂ inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials – European Heart Journal (link para o resumo – $ para o texto completo)

Comentário: Another Win for Guided P2Y12 Therapy in ACS: Meta-analysis – TCTMD

Comentário no Twitter

Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials: read more in EHJ!https://t.co/oAehSfPVdt#cardiotwitter @ESC_Journals @escardio pic.twitter.com/AEuH7V6IkR

— EHJ Editor-in-Chief (@ehj_ed) December 23, 2021